Greenwich LifeSciences, Inc. ( GLSI ) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for the FLAMINGO-01 Phase III clinical trial.

Greenwich LifeSciences ( GLSI ) stock is among today’s top performers. What’s driving GLSI stock higher?

FDA Clears First Commercial GP2 Lot for Phase III Trial

The company said the FDA reviewed and approved the first commercial lot of finished GP2 vials for use in FLAMINGO-01 in the United States. The GP2 active ingredient was manufactured in an approved commercial facility in 2023, with vial filling completed in 2024, and stability programs initiated for all lots.

Greenwich LifeSciences ( GLSI ) said data from the commercial manufacturing and stability programs was submitted to the FDA and cleared for clinical use following the agency's review. The company plans to begin using the newly approved GP2 vials at all 40 U.S. trial sites in the coming weeks.

The company said the approval supports preparation for a future Biologics License Application filing for GLSI-100, with additional commercial lots planned to support both clinical and manufacturing data requirements for regulatory review in the U.S. and other countries.

GLSI Trades Above Key Levels

Currently, the stock is trading 27.8% above its 20-day simple moving average (SMA) and 112.5% above its 100-day SMA, demonstrating strong short-term and longer-term strength. Shares have increased 75.45% over the past 12 months and are currently positioned closer to their 52-week highs than lows, indicating a robust upward trend.

The RSI is at 54.35, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that while the stock is performing well, there may be some underlying weakness that traders should monitor.

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Greenwich LifeSciences ( GLSI ), highlighting its strengths and weaknesses compared to the broader market:

Momentum: Bullish (Score: 94.47) — The stock is outperforming the broader market.

The Verdict: Greenwich LifeSciences’s Benzinga Edge signal reveals a strong momentum setup. The high momentum score indicates that the stock is in a favorable position, suggesting that investors may want to capitalize on this upward trend.

GLSI Price Action: At the time of writing, Greenwich shares are trading 9.55% higher at $24.43, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.